PDFNJ's Youth Drug Prevention Campaign and Societal Cost Savings

The Partnership for a Drug-Free New Jersey (PDFNJ) has announced the winners of its 2026 4th-grade bookmark contest, reinforcing its youth prevention education efforts. The non-profit organization, PDFNJ, disseminates prevention messages throughout New Jersey, supported by approximately $200 million in pro bono media advertising. These early education campaigns delay the onset of substance abuse, creating macroeconomic value by reducing long-term national healthcare costs. Youth prevention education is more than just saving individual lives; it is considered the most cost-effective investment in preventing the influx of future potential opioid use disorder (OUD) patients.

Rapid Growth in the Global OUD Treatment Market

As the importance of youth prevention education increases, the market for treatments for existing opioid use disorder (OUD) patients is also growing rapidly. The global OUD treatment market is expected to grow from approximately $5.9 billion in 2025 to a maximum of $16.75 billion by 2035, with an annual growth rate of approximately 11%. This growth is driven by the opioid crisis sweeping across the United States and the expansion of government support for medication-assisted treatment (MAT). As a result, the market competitiveness of pharmaceutical companies developing long-acting injection (LAI) treatments is attracting significant attention.

Indivior Sublocade's Dominant Market Share and Clinical Position

Leading this market is Indivior PLC (INDV)'s Sublocade (buprenorphine extended-release). Sublocade, which acts as a partial agonist on the mu-opioid receptor in the brain, is the first once-monthly injectable, extended-release formulation that eliminates the inconvenience of daily administration of existing film-based treatments. In October 2017, it received a highly favorable recommendation for approval from the FDA Advisory Committee (AdComm) with 18 votes in favor and 1 against, and received final approval on November 30 of the same year. Sublocade's net sales grew from $756 million in 2024 to $856 million in 2025, a growth of approximately 13%, solidifying its position as a blockbuster drug.

Changes in Competitive Landscape and Valuation Benchmark for Technology Licensing Deals

In the OUD treatment market, various drugs with different mechanisms of action are competing fiercely, in addition to Sublocade. Representative competing drugs include Vivitrol (naltrexone extended-release) from Alkermes plc (ALKS) and Brixadi (buprenorphine extended-release), developed by Camurus AB (CAMX) and licensed to Braeburn Pharmaceuticals for distribution in the United States. In particular, the license agreement signed by Camurus in 2014 to transfer the U.S. rights for Brixadi to Braeburn included an upfront payment of $20 million and milestone payments of up to $151 million, becoming a major valuation standard in the industry.

Why This Matters

With the global opioid use disorder (OUD) treatment market growing rapidly from $5.9 billion in 2025 to $16.75 billion in 2035, the sales growth of Indivior (INDV)'s Sublocade demonstrates its dominance in the long-acting injectable (LAI) market. Sublocade, which received a 18-to-1 recommendation for approval from the FDA Advisory Committee (AdComm) and was subsequently launched, surpassed $856 million in net sales in 2025, demonstrating its ability to establish a strong market entry barrier against competitors such as Camurus (CAMX)'s Brixadi and Alkermes (ALKS)'s Vivitrol. From an R&D perspective, the extension of the duration of mu-opioid receptor-targeting formulations and the improvement of medication adherence technology will serve as key benchmarks for evaluating next-generation pipelines. Furthermore, the total deal value of $171 million secured by Camurus through its licensing agreement with Braeburn provides a practical guideline for valuing similar OUD assets held by emerging biotech companies.